NEW MODIFIED RECOMBINANT BOTULINUM NEUROTOXIN TYPE F WITH ENHANCED POTENCY

被引：0
|
作者：
Burgin, Dave [1 ]
Perier, Cindy [2 ]
Elliot, Mark [1 ]
Hornby, Fraser [1 ]
Mir, Imran [1 ]
Beard, Matthew [1 ]
机构：
[1] Ipsen Bioinnovat, 102 Pk Dr, Abingdon OX14 4RY, Oxon, England
[2] Ipsen Innovat, Les Ulis, France
来源：
TOXICON | 2018年 / 156卷
关键词：
Activation loop; Botulinum neurotoxin (BoNT); Potency;
D O I：
10.1016/j.toxicon.2018.11.036
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
26
引用
收藏
页码：S12 / S13
页数：2
相关论文
共 50 条
  • [41] Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody
    Nowakowski, A
    Wang, C
    Powers, DB
    Amersdorfer, P
    Smith, TJ
    Montgomery, VA
    Sheridan, R
    Blake, R
    Smith, LA
    Marks, JD
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) : 11346 - 11350
  • [42] CHIMERIC BOTULINUM NEUROTOXIN A-B HAS HIGHER NEUROMUSCULAR BLOCKADE POTENCY COMPARED TO BOTULINUM NEUROTOXIN A IN SMOOTH MUSCLE OF THE MOUSE
    Thaker, Hatim
    Zhang, Jie
    Cristofaro, Vivian
    Adam, Rosalyn
    Sullivan, Maryrose
    Dong, Min
    NEUROUROLOGY AND URODYNAMICS, 2023, 42 : S8 - S9
  • [43] Establishment of an alternative potency test for botulinum neurotoxin type A using muscle action potential change in rats
    Goto, Y.
    Torii, Y.
    Sakamoto, T.
    Kaji, R.
    Takahashi, M.
    Nakahira, S.
    Ginnaga, A.
    TOXICON, 2013, 68 : 87 - 88
  • [44] Validation of the T-47D Cell Culture Bioassay for the Potency Assessment of Botulinum Neurotoxin Type A
    Xavier, Bruna
    Dumoncel, Rafaela Ferreira Perobelli
    Cardoso Jr, Clovis Dervil Appratto
    da Silva, Francielle Santos
    Dalmora, Sergio Luiz
    CURRENT PHARMACEUTICAL ANALYSIS, 2023, 19 (04) : 345 - 351
  • [45] An Overview of Clinical Trial Data on a New Formulation of Botulinum Neurotoxin Type A
    Jewell, Mark L.
    Monheit, Gary D.
    AESTHETIC SURGERY JOURNAL, 2009, 29 (06) : S31 - S33
  • [46] Potency and stability of a trivalent, catalytically inactive vaccine against botulinum neurotoxin serotypes C, E and F (triCEF)
    Webb, Robert
    Wright, Patrick M.
    Brown, Jennifer L.
    Skerry, Janet C.
    Guernieri, Rebecca L.
    Smith, Theresa J.
    Stawicki, Christopher
    Smith, Leonard A.
    TOXICON, 2020, 176 : 67 - 76
  • [47] Enhanced Neutralization Potency of Botulinum Neurotoxin Antibodies Using a Red Blood Cell-Targeting Fusion Protein
    Adekar, Sharad P.
    Segan, Andrew T.
    Chen, Cindy
    Bermudez, Rodney
    Elias, M. D.
    Selling, Bernard H.
    Kapadnis, B. P.
    Simpson, Lance L.
    Simon, Paul M.
    Dessain, Scott K.
    PLOS ONE, 2011, 6 (03):
  • [48] Superactivation of the botulinum neurotoxin serotype a light chain metalloprotease: A new wrinkle in botulinum neurotoxin
    McAllister, LA
    Hixon, MS
    Kennedy, JP
    Dickerson, TJ
    Janda, KD
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (13) : 4176 - 4177
  • [49] WHAT DEFINES A BOTULINUM NEUROTOXIN-IN VIVO POTENCY IS THE PRIMARY PROPERTY
    Johnson, Eric A.
    TOXICON, 2018, 156 : S52 - S52
  • [50] Characterization of the genes encoding the botulinum neurotoxin complex in a strain of Clostridium botulinum producing type B and F neurotoxins
    Santos-Buelga, JA
    Collins, MD
    East, AK
    CURRENT MICROBIOLOGY, 1998, 37 (05) : 312 - 318
12345